ArticleBritish journal of cancer2009
The impact of healthcare costs in the last year of life and in all life years gained on the cost-effectiveness of cancer screening.
Article in British journal of cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Evaluation of the Effectiveness and Cost-Effectiveness of Personalized Surveillance After Colorectal Adenomatous Polypectomy.Epidemiologic reviews · 2017Pooled it
- Colorectal Cancer: Cost-effectiveness of Colonoscopy versus CT Colonography Screening with Participation Rates and Costs.Radiology · 2018Trial
- Cost-effectiveness of colon capsule endoscopy in colorectal cancer screening: a modeling study.Endoscopy · 2025Article
- The health and long-term care costs in the last year of life in The Netherlands.The European journal of health economics : HEPAC : health economics in prevention and care · 2025Article
- Advance directives completion and hospital out-of-pocket expenditures.Journal of hospital medicine · 2022Article
- Chemotherapy and molecular targeting therapy for recurrent cervical cancer.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2016Article
- Cost-effective analysis of topical chlorhexidine in hematologic patients at risk for oral mucositis.Clinical oral investigations · 2015Article
- The effect of caregiving on bereavement outcome: study protocol for a longitudinal, prospective study.BMC palliative care · 2015Article
- Article
- Lifetime costs of the top five cancers in Taiwan.The European journal of health economics : HEPAC : health economics in prevention and care · 2012Article
- Standardizing the inclusion of indirect medical costs in economic evaluations.PharmacoEconomics · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is under debate whether healthcare costs related to death and in life years gained (LysG) due to life saving interventions should be included in economic evaluations. We estimated the impact of including these costs on cost-effectiveness of cancer screening. We obtained health insurance, home care, nursing homes, and mortality data for 2.1 million inhabitants in the Netherlands in 1998-1999. Costs related to death were approximated by the healthcare costs in the last year of life (LastYL), by cause and age of death. Costs in LYsG were estimated by calculating the healthcare costs in any life year. We calculated the change in cost-effectiveness ratios (CERs) if unrelated healthcare costs in the LastYL or in LYsG would be included. Costs in the LastYL were on average 33% higher for persons dying from cancer than from any cause. Including costs in LysG increased the CER by 4040 euro in women, and by 4100 euro in men. Of these, 660 euro in women, and 890 euro in men, were costs in the LastYL. Including unrelated healthcare costs in the LastYL or in LYsG will change the comparative cost-effectiveness of healthcare programmes. The CERs of cancer screening programmes will clearly increase, with approximately 4000 euro. However, because of the favourable CER's, including unrelated healthcare costs will in general have limited policy implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.